Camptothecin Analogs With 10-Amino Linkers for Stable Immunoconjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing camptothecin (CPT) derivatives face challenges such as poor solubility, stability, and less than desired activity in physiological conditions, limiting their clinical development as chemotherapeutic agents.
Innovation Solution
Novel CPT analogs with an amino group at position 10 for conjugation to a linker, allowing for fine-tuning of the payload, enhancing potency, stability, and solubility, suitable for use alone or in immunoconjugates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CPT derivatives are used, then cytotoxic activity is achieved, but solubility and stability in physiological conditions are poor
Solution Approach 1:
The patent modifies the chemical structure of CPT by changing parameters at specific positions: introducing an amino group at position 10 and varying substituents at position 7 (R7). These structural parameter changes optimize both solubility and stability while maintaining cytotoxic activity, directly resolving the contradiction between reliability and harmful factors.
Solution Approach 2:
The patent applies local modifications to specific positions in the CPT molecule. The amino group at position 10 provides conjugation capabilities and improved solubility, while the R7 substituent is optimized for stability. This localized optimization allows different parts of the molecule to address different issues simultaneously.
2Object-generated harmful factors
If CPT derivatives are modified to improve solubility, then solubility improves, but potency and stability may be compromised
Solution Approach 1:
The patent systematically varies chemical parameters (amino group at position 10, R7 substituents) to identify optimal combinations that simultaneously achieve good solubility and high potency. The structured approach to parameter modification ensures that improvements in one area do not compromise another.
3Productivity
If existing CPT analogues are developed, then some activity is achieved, but stability and immunogenicity are less than desired
Solution Approach 1:
The patent modifies CPT analogues by changing key structural parameters - specifically introducing the amino group at position 10 and optimizing R7 - to achieve both high activity and high stability. This resolves the contradiction by finding parameter combinations that satisfy both requirements simultaneously.
Data Source
AI summary
The invention provides novel camptothecin analogs and immunoconjugates thereof, as well as pharmaceutical compositions and methods of preparation and use for treating various diseases and disorders (e.g., cancer).